切换至 "中华医学电子期刊资源库"

中华诊断学电子杂志 ›› 2019, Vol. 07 ›› Issue (01) : 63 -65. doi: 10.3877/cma.j.issn.2095-655X.2019.01.013

所属专题: 文献

综述

蛋白质组学在帕金森病诊断中的研究进展
樊开阳1, 孙强2, 张瑜3, 卢丽丽4, 宋佳鑫4, 王兆京4, 马莉4,()   
  1. 1. 272029 济宁医学院附属医院医务处;116044 大连医科大学流行病教研室
    2. 272029 济宁医学院附属医院医务处
    3. 116021 大连市疾病预防控制中心
    4. 116044 大连医科大学流行病教研室
  • 收稿日期:2018-02-26 出版日期:2019-02-26
  • 通信作者: 马莉
  • 基金资助:
    国家自然科学基金(81200989)

Progress of proteomics in the diagnosis of Parkinson′s disease

Kaiyang Fan1, Qiang Sun2, Yu Zhang3, Lili Lu4, Jiaxin Song4, Zhaojing Wang4, Li Ma4,()   

  1. 1. Medical Service, the Affiliated Hospital of Jining Medical University, Jining 272029, China
    3. Dalian Center for Disease Control and Prevention, Dalian 116021, China
    4. Department of Epidemiology, Dalian Medical University, Dalian 116044, China
  • Received:2018-02-26 Published:2019-02-26
  • Corresponding author: Li Ma
  • About author:
    Corresponding author: Ma Li, Email:
引用本文:

樊开阳, 孙强, 张瑜, 卢丽丽, 宋佳鑫, 王兆京, 马莉. 蛋白质组学在帕金森病诊断中的研究进展[J/OL]. 中华诊断学电子杂志, 2019, 07(01): 63-65.

Kaiyang Fan, Qiang Sun, Yu Zhang, Lili Lu, Jiaxin Song, Zhaojing Wang, Li Ma. Progress of proteomics in the diagnosis of Parkinson′s disease[J/OL]. Chinese Journal of Diagnostics(Electronic Edition), 2019, 07(01): 63-65.

帕金森病是人类第二大神经退行性疾病,对于其发病机制目前尚不清楚,而运用蛋白质组学方法对该疾病进行研究,有助于对该疾病进行更加深入的了解,对探明其发病机制,寻找可靠的相关生物学标记物,开拓新的治疗方法具有重要意义。笔者主要从两个方面介绍蛋白质组学在帕金森病研究中的应用,一方面是通过获取患者本身的脑部组织和脑脊液进行蛋白研究,另一方面通过制作帕金森病动物模型获得需要的组织进行蛋白研究。

Parkinson′s disease is the second most common neurodegenerative disease in humans. The pathogenesis of Parkinson′s disease is currently unclear. Using proteomics approach to study the disease can help us to have a deeper understanding of the disease, and it is of great significance to explore its pathogenesis, to find reliable related biomarkers, and to develop new treatments. The author introduces the application of proteomics in the study of Parkinson′s disease from two aspects. On the one hand, the proteins is studies by acquiring the brain tissue and cerebrospinal fluid of the patients. On the other hand, the desired tissue is obtained for protein tissue research by making animal models of Parkinson′s disease.

[1]
Wirdefeldt K, Adami HO, Cole P,et al.Epidemiology and etiology of Parkinson′s disease:a review of the evidence[J].Eur J Epidemiol,2011,26(Suppl1):S1-S58.
[2]
Hirtz D, Thurman DJ, Gwinn-Hardy K,et al.How common are the " common" neurologic disorders[J].Neurology,2007,68(5):326-337.
[3]
中华医学会神经病学分会帕金森病及运动障碍学组.中国帕金森病治疗指南(第三版)[J].中华神经科杂志,2014,47(6):428-433.
[4]
刘疏影,陈彪.帕金森病流行现状[J].中国现代神经疾病杂志,2016,16(2):98-101.
[5]
Sharma S, Moon CS, Khogali A,et al.Biomarkers in Parkinson′s disease (recent update)[J].Neurochem Int,2013,63(3):201-229.
[6]
Pan S, Shi M, Jin J,et al.Proteomics identification of proteins in human cortex using multidimensional separations and MALDI tandem mass spectrometer[J].Mol Cell Proteomics,2007,6(10):1818-1823.
[7]
Fountoulakis M, Hardmeier R, Hoger H,et al.Postmortem changes in the level of brain proteins[J].Exp Neurol,2001,167(1):86-94.
[8]
Licker V, Kovari E, Hochstrasser DF,et al.Proteomics in human Parkinson′s disease research[J].J Proteomics,2009,73(1):10-29.
[9]
Basso M, Giraudo S, Corpillo D,et al.Proteome analysis of human substantia nigra in Parkinson's disease[J].Proteomics,2004,4(12):3943-3952.
[10]
Werner CJ, Heyny-von Haussen R, Mall G,et al.Proteome analysis of human substantia nigra in Parkinson's disease[J].Proteome Sci,2008 (6):8.
[11]
Shi M, Jin J, Wang Y, et al. Mortalin:a protein associated with progression of parkinson disease? [J].J Neuropathol Exp Neurol,2008,67(2):117-124.
[12]
陈涛,唐北沙,廖小平.α-突触核蛋白在帕金森病发病机制中的作用[J].中国神经科杂志,2006,39(6):415-418.
[13]
徐丽,曹学兵,孙圣刚,等.鱼藤酮诱导细胞内泛素化α-synuclein聚集选择性损伤多巴胺神经元[J].中国神经免疫学和神经病学杂志,2007(1):35-39.
[14]
Andersen AD, Binzer M, Stenager E, et al. Cerebrospinal fluid biomarkers for Parkinson′s disease-a systematic review[J].Acta Neurol Scand,2017,135(1):34-56.
[15]
Sinha A, Srivastava N, Singh S,et al.Identification of differentially displayed proteins in cerebrospinal fluid of Parkinson′s disease patients:a proteomic approach[J].Clin Chim Acta,2009,400(1/2):14-20.
[16]
Zhang X, Yin X, Yu H,et al.Quantitative proteomic analysis of serum proteins in patients with Parkinson′s disease using an isobaric tag for relative and absolute quantification labeling,two-dimensional liquid chromatography,and tandem mass spectrometry[J].Analyst,2012,137(2):490-495.
[17]
Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of parkinson′s disease[J].Brain,2010,133(3):713-726.
[18]
Bonifati V, Rizzu P, Squitieri F,et al.DJ-1(PARK7),a novel gene for autosomal recessive,early onset parkinsonism[J].Neurol Sci,2003,24(3):159-160.
[19]
Taira T, Saito Y, Niki T,et al.DJ-1 has a role in antioxidative stress to prevent cell death[J].EMBO Rep,2004,5(2):213-218.
[20]
Shi M, Zabetian CP, Hancock AM,et al.Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease[J].Neurosci Lett,2010,480(1):78-82.
[21]
Sowell RA, Owen JB, Butterfield DA.Proteomics in animal models of Alzheimer′s and Parkinson′s diseases[J].Ageing Res Rev,2009,8(1):1-17.
[22]
Waxman EA, Giasson BI.Molecular mechanisms of alpha-synuclein neurodegeneration[J].Biochim Biophys Acta,2009,1792(7):616-624.
[23]
Valastro B, Dekundy A, Krogh M,et al.Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia[J].J Neurochem,2007,102(4):1395-1409.
[24]
Dawson TM, Dawson VL.Molecular pathways of neurodegeneration in parkinson's disease[J].Science,2003,302(5646):819-822.
[25]
Skold K, Svensson M, Nilsson A,et al.Decreased striatal levels of PEP-19 following MPTP lesion in the mouse[J].J Proteome Res,2006,5(2):262-269.
[26]
Putkey JA, Kleerekoper Q, Gaertner TR,et al.A new role for IQ motif proteins in regulating calmodulin function[J].J Biol Chem,2003,278(50):49667-49670.
[27]
McLaughlin P, Zhou Y, Ma T,et al.Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity[J].Glia,2006,53(6):567-582.
[1] 周涵, 武胡雯, 张培深, 邓晗彬, 范闻轩, 李嘉诚, 程少文. 蛋白质组学在慢性难愈合创面研究中的应用进展[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 536-540.
[2] 张春玉, 陈海云, 肖忠萍, 罗琴, 潘运昌. 血清NT-proBNP 预测肺栓塞心脏功能障碍的临床分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 805-808.
[3] 孙璐, 蒋亚玲, 陈凌君. 布托啡诺对脑缺血再灌注损伤大鼠神经炎症和JAK2/STAT3信号通路的影响[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(06): 344-350.
[4] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[5] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[6] 谢井伟, 王森, 王非, 郭永坤. STA-MCA血管搭桥术治疗烟雾病[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(05): 318-320.
[7] 江西省神经外科质量控制中心. 江西省心源性脑卒中多学科协作防治专家共识[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(05): 264-277.
[8] 张洪, 杨琪, 罗静, 唐茜, 邓鸿, 巩文艳, 王丽坤, 刘静, 艾双春. 多靶点神经调控技术对卒中后上肢运动功能障碍患者的脑网络功能连接研究[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(05): 278-284.
[9] 王如海, 王绅, 张敏, 李春, 韩超, 于强, 胡海成, 李习珍. 重型创伤性脑损伤患者去骨瓣减压术后短期死亡风险的影响因素分析[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(05): 285-291.
[10] 许方军, 曹晓光, 王修敏, 王婷, 陈冬冬, 余程冬, 张鹤言. 基于闭环理论的动作观察疗法联合躯干控制训练对脑卒中后下肢运动的影响[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(05): 292-299.
[11] 司楠, 孙洪涛. 创伤性脑损伤后肾功能障碍危险因素的研究进展[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(05): 300-305.
[12] 张雅文, 尹昱, 陈江龙, 杨玉慧, 吕红香, 张琦, 吕佩源. Theta爆发式经颅磁刺激治疗失语症的研究进展[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(05): 306-311.
[13] 陈冬冬, 余程冬, 曹晓光. 上肢外骨骼机器人在脑卒中康复中的应用与研究进展[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(05): 312-317.
[14] 惠泉, 孙方昱, 赵欣, 许青, 李奕, 陈建雄, 吴立, 郑伟燕. 急性间歇性卟啉病HMBS基因新发缺失突变一例[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 507-511.
[15] 李璇, 邓岚, 郭微, 邓永梅, 刘杰昕. 标准化皮肤管理流程在防治脑卒中患者失禁相关性皮炎中的应用[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(05): 479-482.
阅读次数
全文


摘要